The end of the line is looming for Oxurion, after a clinical trial of its last pipeline drug for diabetic macular oedema (DME) failed to meet its primary endpoint.
Oxurion will carry out an interim analysis of a phase 2 trial of its last remaining clinical asset – THR-149 for diabetic macular oedema (DME) – before the end of this year as it tries to g
A higher dose of Regeneron and Bayer's Eylea given every three or four months has shown efficacy in a pair of clinical trials, in a big boost for the multibillion-dollar product.
Shares in Belgian biotech Oxurion are taking a hammering this morning after it reported that one of its drugs for diabetic eye disease had failed a phase 2 trial and will be terminated.
There is plenty of evidence that Novartis' ophthalmology drug Beovu can match its rivals when it comes to efficacy, with less frequent dosing, but the big question facing the company is whe
Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl